» Articles » PMID: 26099252

Alterations of Bacteroides Sp., Neisseria Sp., Actinomyces Sp., and Streptococcus Sp. Populations in the Oropharyngeal Microbiome Are Associated with Liver Cirrhosis and Pneumonia

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2015 Jun 24
PMID 26099252
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The microbiomes of humans are associated with liver and lung inflammation. We identified and verified alterations of the oropharyngeal microbiome and assessed their association with cirrhosis and pneumonia.

Methods: Study components were as follows: (1) determination of the temporal stability of the oropharyngeal microbiome; (2) identification of oropharyngeal microbial variation in 90 subjects; (3) quantitative identification of disease-associated bacteria. DNAs enriched in bacterial sequences were produced from low-biomass oropharyngeal swabs using whole genome amplification and were analyzed using denaturing gradient gel electrophoresis analysis.

Results: Whole genome amplification combined with denaturing gradient gel electrophoresis analysis monitored successfully oropharyngeal microbial variations and showed that the composition of each subject's oropharyngeal microbiome remained relatively stable during the follow-up. The microbial composition of cirrhotic patients with pneumonia differed from those of others and clustered together in subgroup analysis. Further, species richness and the value of Shannon's diversity and evenness index increased significantly in patients with cirrhosis and pneumonia versus others (p < 0.001, versus healthy controls; p < 0.01, versus cirrhotic patients without pneumonia). Moreover, we identified variants of Bacteroides, Eubacterium, Lachnospiraceae, Neisseria, Actinomyces, and Streptococcus through phylogenetic analysis. Quantitative polymerase chain reaction assays revealed that the populations of Bacteroides, Neisseria, and Actinomycetes increased, while that of Streptococcus decreased in cirrhotic patients with pneumonia versus others (p < 0.001, versus Healthy controls; p < 0.01, versus cirrhotic patients without pneumonia).

Conclusions: Alterations of Bacteroides, Neisseria, Actinomyces, and Streptococcus populations in the oropharyngeal microbiome were associated with liver cirrhosis and pneumonia.

Citing Articles

Oropharyngeal microbiome profiling and its association with age and heart failure in the elderly population from the northernmost province of China.

Liu J, He X, Yang K, Zhao Y, Dai E, Chen W Microbiol Spectr. 2024; 12(10):e0021624.

PMID: 39162522 PMC: 11448084. DOI: 10.1128/spectrum.00216-24.


Association between oral microbial dysbiosis and poor functional outcomes in stroke-associated pneumonia patients.

Ren Y, Liang J, Li X, Deng Y, Cheng S, Wu Q BMC Microbiol. 2023; 23(1):305.

PMID: 37875813 PMC: 10594709. DOI: 10.1186/s12866-023-03057-8.


Diurnal changes of the oral microbiome in patients with alcohol dependence.

Li X, Zhao K, Chen J, Ni Z, Yu Z, Hu L Front Cell Infect Microbiol. 2022; 12:1068908.

PMID: 36579346 PMC: 9791055. DOI: 10.3389/fcimb.2022.1068908.


Shen-Ling-Bai-Zhu-San Enhances the Antipneumonia Effect of Cefixime in Children by Ameliorating Gut Microflora, Inflammation, and Immune Response.

Feng J, Zhang C, Chen H, Chen Z, Chen Y, He D Evid Based Complement Alternat Med. 2022; 2022:7752426.

PMID: 36118084 PMC: 9473888. DOI: 10.1155/2022/7752426.


Human disease prediction from microbiome data by multiple feature fusion and deep learning.

Chen X, Zhu Z, Zhang W, Wang Y, Wang F, Yang J iScience. 2022; 25(4):104081.

PMID: 35372808 PMC: 8971930. DOI: 10.1016/j.isci.2022.104081.


References
1.
Zaura E, Keijser B, Huse S, Crielaard W . Defining the healthy "core microbiome" of oral microbial communities. BMC Microbiol. 2009; 9:259. PMC: 2805672. DOI: 10.1186/1471-2180-9-259. View

2.
Zhou L, Srisatjaluk R, Justus D, Doyle R . On the origin of membrane vesicles in gram-negative bacteria. FEMS Microbiol Lett. 1998; 163(2):223-8. DOI: 10.1111/j.1574-6968.1998.tb13049.x. View

3.
Forsythe P . Probiotics and lung diseases. Chest. 2011; 139(4):901-908. DOI: 10.1378/chest.10-1861. View

4.
Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D . Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011; 54(2):562-72. DOI: 10.1002/hep.24423. View

5.
Bonnel A, Bunchorntavakul C, Reddy K . Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011; 9(9):727-38. DOI: 10.1016/j.cgh.2011.02.031. View